Pulmonary Hypertension News and Research RSS Feed - Pulmonary Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Pulmonary neuroendocrine cells act like sensor to orchestrate immune response

Pulmonary neuroendocrine cells act like sensor to orchestrate immune response

An uncommon and little-studied type of cell in the lungs has been found to act like a sensor, linking the pulmonary and central nervous systems to regulate immune response in reaction to environmental cues. [More]
Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Laboratorios SALVAT, S.A. and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited, jointly announced today the signing of an exclusive License and Supply Agreement for the marketing and distribution of Duoxal ear drops (patented combination solution of Ciprofloxacin and Fluocinolone Acetonide) in the People's Republic of China, Hong Kong S.A.R., Macau S.A.R., and Taiwan and an option to add Thailand to the contractual territory. [More]
ISHLT issues new list of criteria to determine patient eligibility for heart transplant

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

To determine patient eligibility for heart transplant, the International Society for Heart Lung Transplantation maintains a list of criteria, first issued in 2006, that acts as a guideline for physicians. [More]
SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC). [More]
Selexipag holds promise for treatment of pulmonary hypertension

Selexipag holds promise for treatment of pulmonary hypertension

Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine. [More]
Vagus nerve stimulation prevents hemorrhagic complications following surgery

Vagus nerve stimulation prevents hemorrhagic complications following surgery

Stimulating the vagus nerve is a potentially efficacious and safe way to stop the flow of blood and prevent hemorrhagic complications following surgery and other invasive procedures, according to a researcher in the Center for Bioelectronic Medicine at The Feinstein Institute for Medical Research. [More]
Study reveals pathogenetic role of miR-125a in pulmonary hypertension

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

Pulmonary hypertension is an umbrella term used for many conditions that all result in elevation of the pulmonary arterial pressure. Of interest, many of these completely different clinical and pathophysiological entities result in a final common pathway of vasoconstriction, micro thrombosis and vascular remodelling. [More]
FIRS calls for continued international support to end AIDS epidemic by 2030

FIRS calls for continued international support to end AIDS epidemic by 2030

World AIDS Day, held annually on the first day of December each year since 1988, is an opportunity for people around the world to join in the fight, show their support for those living with human immunodeficiency virus (HIV), and commemorate the lives of those who have died. [More]
Fat cells produced from bone marrow may be linked to chronic diseases

Fat cells produced from bone marrow may be linked to chronic diseases

Researchers at the University of Colorado Anschutz Medical Campus have found that fat cells produced by stem cells from the bone marrow may be linked to chronic illnesses like diabetes, cardiovascular disease, kidney disease and some cancers. [More]

Haemodynamic variables may distinguish pre- from post-capillary PH

Researchers have identified the haemodynamic variables that best distinguish between patients with idiopathic pulmonary arterial hypertension and isolated post-capillary pulmonary hypertension. [More]
Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that INOmax (nitric oxide) for inhalation has received regulatory approval in Australia and Japan for pulmonary hypertension in conjunction with heart surgery. [More]
Invitae announces dramatic expansion of genetic testing menu

Invitae announces dramatic expansion of genetic testing menu

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin releasing the new content between now and the end of the year. Invitae is immediately expanding its menu with dozens of new test panels for hereditary cancer, cardiovascular, neuromuscular, pediatric and other rare disorders. [More]
Pitt investigators to lead $15 million federal initiative to manage breathing disorder clinical trials

Pitt investigators to lead $15 million federal initiative to manage breathing disorder clinical trials

The University of Pittsburgh Graduate School of Public Health and School of Medicine investigators will be leading a $15 million, five-year federal initiative to manage national clinical trials aimed at developing new treatments for breathing disorders. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. [More]

Mitral valve disease patients enrolled in Harpoon’s Early Feasibility Study with 100% procedural success

Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe. [More]
VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

Two members of the vascular endothelial growth factor family are highly specific and moderately sensitive for the presence of pulmonary hypertension, report researchers. [More]
PAH treatments less effective in CTD-associated disease

PAH treatments less effective in CTD-associated disease

Patients with connective tissue disease-associated pulmonary arterial hypertension have a poorer response to advanced PAH treatments than those with idiopathic disease, finds a meta-analysis. [More]
Exercise training improves quality of life for patients with pulmonary hypertension

Exercise training improves quality of life for patients with pulmonary hypertension

Exercise training for patients with pulmonary hypertension was shown to be safe and to improve quality of life, according to an analysis by UT Southwestern Medical Center cardiologists of studies involving more than 400 participants. [More]
New treatment algorithm for pulmonary arterial hypertension launched in 2015 ESC/ERS Guidelines

New treatment algorithm for pulmonary arterial hypertension launched in 2015 ESC/ERS Guidelines

A novel treatment algorithm for pulmonary arterial hypertension is launched today in new pulmonary hypertension guidelines from the European Society of Cardiology and European Respiratory Society. [More]
Advertisement
Advertisement